Disease Domain | Count |
---|---|
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Synthetic peptide | 1 |
Target |
Mechanism GLP-1R agonists |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NTRK inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 Jan 2025 |
Sponsor / Collaborator |
Start Date08 May 2023 |
Sponsor / Collaborator |
Start Date21 Oct 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Albenatide ( GLP-1R ) | Diabetes Mellitus, Type 2 More | NDA/BLA |
CSCJC3456 | Advanced Malignant Solid Neoplasm More | Phase 1 |
CSCJC-4523 ( FGFRs ) | Neoplasms More | Preclinical |
NANT-3456 ( NTRK ) | Neoplasms More | Preclinical |